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The inositol 1,4,5-trisphosphate receptor-associated
cGMP kinase substrate (IRAG) is highly expressed in
platelets. It is assembled in a macrocomplex together with
cGMP-dependent protein kinase Iβ (cGKIβ) and the inosi-
tol 1,4,5-trisphosphate receptor type I (IP3RI). In response
to cGKI activation, IRAG is phosphorylated in vivo. By
mass spectrometric analysis of purified in vivo phosphor-
ylated IRAG from cGMP-stimulated human platelets,
Ser664 and Ser677 were identified as phosphorylated
amino acids. Generation of phosphospecific antibodies
confirmed these in vivo phosphorylation sites. To exam-
ine the role of IRAG in platelet function, we analysed the
aggregation of platelets from an IRAG mouse mutant
(IRAG∆12/∆12). In this mutant, exon 12 of the IRAG gene
was deleted and thereby the IRAG-IP3RI interaction was
abolished [1]. Interestingly, collagen-induced aggregation
of IRAG∆12/∆12 platelets was not inhibited by nitric oxide
(NO) and the cGMP analogue 8-pCPT-cGMP in contrast
to wild type platelets. The shape change was not affected,
neither in mutant nor in wild type platelets. However, ilo-
prost and the cAMP-analogue cBIMPS still inhibited
aggregation and shape change in IRAG∆12/∆12 and wild
type platelets. Additionally, we analysed fibrinogen bind-
ing to thrombin-stimulated platelets. In wild type plate-
lets, pre-treatment with NO and cGMP decreased
fibrinogen binding by about 50%. In contrast, in IRAG∆12/
∆12 platelets the response to NO and cGMP was nearly
absent. Preincubation with iloprost and cBIMPS clearly
reduced agonist-induced fibrinogen binding to both,
IRAG∆12/∆12 and wild type platelets. These results suggest
that signalling through IRAG/IP3RI is essential for NO/
cGMP-dependent inhibition of platelet aggregation and
activation of the fibrinogen receptor
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